相关实验视频
Updated: Sep 18, 2025

11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
38.4K
关于DMT对神经退行症的保护作用
Ede Frecska1, Attila Kovács1, Attila Szabo2
1Department of Psychiatry, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
International review of neurobiology
|June 20, 2025
概括
甲基三胺 (DMT) 通过向西格玛-1受体,显示出对抗脑损伤和神经退行性疾病的神经保护的治疗潜力. 临床前研究表明,DMT可以减轻缺血-再输液损伤和相关的神经病理.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 甲基三胺 (DMT) 作用于血清素和西格玛-1受体 (Sig-1R).
- Sig-1R蛋白在中枢神经系统中高度表达,并与神经系统疾病有关.
- 准Sig-1R和血清素受体可能为诸如中风和阿尔茨海默病等疾病提供治疗益处.
研究的目的:
- 探索DMT的神经保护潜力.
- 调查DMT在减轻缺血-再输液损伤 (IRI) 和神经退行性疾病中的作用.
- 总结关于DMT在IRI和相关神经病理方面的疗效的临床前发现.
主要方法:
- 关于与IRI相关的细胞生物能源中的Sig-1R功能概述.
- 使用DMT进行的体外和体内临床前研究的总结.
- 对DMT对IRI和相关细胞损伤的影响的分析.
主要成果:
- DMT的作用可能源于其作为西格玛-1受体的内源性激动剂的作用.
- 临床前研究表明,DMT可以减轻IRI和相关的细胞神经病理.
- DMT显示有保护各种形式的脑缺血的潜力.
结论:
- 在细胞保护机制中,DMT表现出普遍的作用.
- 德米的神经保护作用表明,在中风和心脏骤停时,它对IRI具有治疗潜力.
- DMT作为一种模型分子,用于开发神经退行性疾病的药理疗法.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.肌缩性侧面硬化症 (AMLS) 是一种疾病.大脑缺血症是什么意思甲基二三胺是什么?缺血-再输液损伤 缺血-再输液损伤神经退行性疾病 神经退行性疾病神经保护是一种神经保护.这是一种血清胺.西格玛-1受体是一个受体.一次性中风,中风.更多相关视频
09:53A Simple One-step Dissection Protocol for Whole-mount Preparation of Adult Drosophila Brains
Published on: December 1, 2016
28.0K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391